12. Assessment of interaction for on study mortality in chemotherapy trials.
| On study mortality, chemotherapy patients | N included | P value for interaction* |
| Total unadjusted (Cox model) | 10441 (100%) | ‐ |
| Patient level characteristics | ||
| Hb at baseline (continuous) | 9945 | 0.8689 |
| Hb at baseline (categorical 1) | 9945 | 0.9035 |
| Hb at baseline (categorical 2) | 9945 | 0.9881 |
| Tumor (categorical 1) | 10399 | 0.1846 |
| Tumor (categorical 2) | 10399 | 0.1509 |
| Sex | 10441 | 0.1395 |
| Age (continuous) | 10430 | 0.5684 |
| Age (categorical) | 10430 | 0.3442 |
| Hct (continuous) | 7849 | 0.5722 |
| Hct (categorical) | 7849 | 0.2189 |
| Baseline serum EPO (continuous) | 3959 | 0.9051 |
| Baseline serum EPO (categorical) | 3959 | 0.2047 |
| ECOG | 8057 | 0.5776 |
| ECOG (0,1,2 vs 3,4) | 8057 | 0.9970 |
| BMI (categorical) | 8882 | 0.6333 |
| History of thromboembolic events | 6667 | 0.1421 |
| History of cardiovascular events | 7369 | 0.9285 |
| History of hypertension | 6667 | 0.6079 |
| History of diabetes mellitus | 5579 | 0.7429 |
| Geographical region [region_cat] | 10053 | 0.3543 |
| Metastatic vs non‐metastatic | 8956 | 0.6083 |
| Planned Hb ceiling (categorical 1) | 10362 | 0.2834 |
| Planned Hb ceiling (categorical 2) | 10362 | 0.3788 |
| Study level characteristics | ||
| Placebo controlled | 10441 | 0.5349 |
| Randomization (adequate vs unclear) | 10441 | 0.8789 |
| Allocation (adequate vs unclear) | 10441 | 0.0722 |
| Endpoint overall survival | 10441 | 0.1117 |
| Year of last patient randomized into study (categorical) | 10441 | 0.1568 |
| Source of data (company versus independent) | 10441 | 0.1842 |
| Iron category | 10441 | 0.5201 |
| Planned ESA treatment duration (categorical) | 10441 | 0.2020 |
| Planned weekly ESA dosage (categorical) | 10441 | 0.2940 |
| Planned frequency ESA administration (categorical) | 10441 | 0.0544 |
*P value for interaction based on LR test, patients with missing data are excluded from LR test